<DOC>
	<DOCNO>NCT01192230</DOCNO>
	<brief_summary>The purpose study examine efficacy safety endostatin combine Docetaxel advance Non-Small-Cell Lung Carcinoma ( NSCLC ) patient failure first-line second-line chemotherapy .</brief_summary>
	<brief_title>Study Endostatin Combined With Docetaxel Treatment Advanced Non-small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Patients diagnose histologic , cytologic diagnosis IIIB ( malignant hydrothorax hydropericardium ) IV nonsmall cell lung cancer ≥ 18 year old patient receive one regimen platinumbased chemotherapy ; patient receive EGFR monoclonal treatment could also enrol At least one target lesion diameter spiral CT ≥ 1 cm , common CT ≥ 2 cm , measure imaging tool interval 4 week last chemo radiotherapy ; 2 week last targeted therapy ECOG 02 Expected life time longer 3 month Normal laboratory value : leucocyte≥ 4×109/L neutrophil≥ 1.5×109/L platelet≥90×109/L Hemoglobin≥ 9g/L ALT AST ≤3×ULN ( ≤5×ULN liver metastasis ) serum creatinine &lt; 1.5 mg/dl bilirubin &lt; 1.5×ULN No allergy biological drug Sign consent form Patients previously receive Docetaxel antiVEGF inhibitor Severe symptomatic heart disease Female patient pregnant lactation period , patient without contraception Severe uncontrolled infection Uncontrolled neurologic psychiatric disease ; Uncontrolled primary metastatic brain tumor Patients malignant tumor , except basal cell carcinoma , squamous cell carcinoma carcinoma situ Patients accept clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Objective response rate</keyword>
	<keyword>Disease control rate</keyword>
	<keyword>Disease free survival</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Quality Live</keyword>
	<keyword>Nonsmall cell lung cancer</keyword>
	<keyword>toxicity</keyword>
</DOC>